



**US FDA completes surveillance inspection of Cohance Life Sciences' API plant located at Nacharam Facility.**

*Received form 483 with 4 observations.*

Hyderabad/Mumbai, March 08, 2024

The United States Food and Drug Administration (US FDA) completed a surveillance inspection of Cohance Lifesciences' API Unit-IV, located in Nacharam, Hyderabad from March 3, 2025 to March 7, 2025.

Following the inspection, the facility received a Form 483 with four observations, which are largely procedural in nature.

We are committed to addressing these observations within the stipulated timeline.

The proposed amalgamation of Suven Pharmaceuticals and Cohance Life Sciences is currently in process and awaiting necessary approvals, (awaiting NCLT and any other required approvals).

**-ENDS-**

**For more information, please visit [www.cohance.com](http://www.cohance.com)**